MBRX (Moleculin Biotech) Pretax Margin %: % (As of Mar. 2026)

What is Moleculin Biotech Pretax Margin %?

Moleculin Biotech MBRX +18.00% 30 Pretax Margin % is % as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 946 Biotechnology companies, Moleculin Biotech ranks worse than 105708.14% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Moleculin Biotech's Pre-Tax Income for the three months ended in Mar. 2026 was $-12.85 Mil. Moleculin Biotech's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Moleculin Biotech's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Moleculin Biotech's Pretax Margin % or its related term are showing as below:

MBRX's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Moleculin Biotech (NAS:MBRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Moleculin Biotech Pretax Margin % Related Terms

Moleculin Biotech Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Moleculin Biotech's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moleculin Biotech Pretax Margin % Chart

Moleculin Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Pretax Margin %

Get a 7-Day Free Trial

0.00

Moleculin Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Pretax Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

MBRX vs ICU, LEXX, INTI: Pretax Margin % Comparison

For the Biotechnology subindustry, Moleculin Biotech's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moleculin Biotech Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Moleculin Biotech's Pretax Margin % falls into.

Save Embed

30GF Score

Moleculin Biotech Inc MBRX

Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Moleculin Biotech Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Moleculin Biotech's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-33.56	/	0
	=	%

Moleculin Biotech's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-12.845	/	0
	=	%

Frequently Asked Questions Learn more about Pretax Margin % →

What does a Pretax Margin % of % mean?

Moleculin Biotech (MBRX) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #999999 out of 946 companies in the Biotechnology industry.

Is Moleculin Biotech's Pretax Margin % too high?

Moleculin Biotech's current Pretax Margin % is %. Based on the distribution chart, Moleculin Biotech ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Moleculin Biotech's Pretax Margin % compare to ICU and LEXX?

According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #999999 out of 946 companies for Pretax Margin %. This places Moleculin Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Pretax Margin % for a Biotechnology company?

A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Pretax Margin % mean?

A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Moleculin Biotech and its competitors. Moleculin Biotech's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Moleculin Biotech stock overvalued right now?

Moleculin Biotech (MBRX) has a current Pretax Margin % of %. The current Pretax Margin % is %. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Pretax Margin % calculated?

Pretax Margin % is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Moleculin Biotech Business Description

Industry Healthcare Biotechnology

Comparable Companies ICU LEXX INTI MTVA CVKD HCWB OSRH COCP HOOK LNAI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0K2H:UK

Address 5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007

Website https://www.moleculin.com

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.

30GF Score

Get the complete analysis for MBRX

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.54

Price

View MBRX Analysis

See Pretax Margin % data for all stocks →